glofitamab,Obinutuzumab 
roche
['glofitamab', 'dlbcl', 'roche']
honorable mention to roche s cd3xcd20 bi-specific glofitamab in r/r dlbcl. this is going to be a real commercial success of a therapy. great to see all the advances with cell therapy and now bi-specifics for these patients. #asco22
#Biotech investor, index provider, entrepreneur, creator of two Nasdaq-listed exchange traded funds, KC native, @univmiami hurricane.????